Date: 2016-11-10
Type of information: Development agreement
Compound: peptide candidates designed to target a G protein-coupled receptor (GPCR) implicated in severe gastro-intestinal disorders
Company: Heptares Therapeutics (UK) Jitsubo (Japan), wholly-owned subsidiaries of Sosei Group (Japan)
Therapeutic area: Gastrointestinal diseases - Digestive diseases
Type agreement: development collaboration
Action mechanism: peptide
Disease:
Details: * On November 10, 2016, Sosei Group's subsidiaries, Heptares Therapeutics and Jitsubo have entered into a collaboration to develop novel peptide candidates designed to target a G protein-coupled receptor (GPCR) implicated in severe gastro-intestinal (GI) disorders. Under the collaboration, Jitsubo will apply its Peptune™ and Molecular Hiving™ peptide engineering technologies and medicinal chemistry capabilities to a GPCR target selected by both Jitsubo and Heptares. Heptares has significant insights into the 3D structure of the receptor via its proprietary StaR® platform. The target GPCR plays an important role in several GI indications and is currently in discovery phase. Heptares will be responsible for development and commercialisation of any peptide candidates that emerge from the collaboration, and will make payments to Jitsubo on achievement of agreed milestones, plus royalties on future sales of any resulting products. No further details are disclosed.
This represents the first strategic collaboration between Sosei subsidiaries.
Financial terms:
Latest news:
